Cite
HARVARD Citation
Jones, G. et al. (2018). PRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry. British journal of cancer. 119 (10), pp. 1233-1243. [Online].